Biopharmaceutical company Aptinyx’s (NASDAQ: APTX) stock price has plunged over 23% premarket on Thursday after the company announced the pricing for its offering of 14 million shares of its common stock.
The company announced that it’s pricing the offering at $3 per share.
Aptinyx has also granted the underwriters a 30-day option to purchase up to 2.1 million additional shares of its common stock at the offering price.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
It is expected that the Illinois-based company will raise $42 million with the money being used to further develop its novel NMDA receptor modulators and for working capital and general corporate purposes.
Just two days ago, the company’s share price jumped over 90% following the announcement of positive results from its Phase 2 study of NYX-783 in patients with PTSD.
However, it has continued to fall since then and is set to wipe out those gain after today’s premarket move.
Its share price is currently trading at $3, after a 23.08% fall premarket on Thursday following the previous day’s 9% loss.
PEOPLE WHO READ THIS ALSO VIEWED:
